NASDAQ:VTVTvTv Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding vTv Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $2.45 -0.01 (-0.41 %) (As of 08/6/2020 04:00 PM ET) Add Compare Share Today's Range$2.37Now: $2.45▼$2.4850-Day Range$2.18MA: $2.41▼$2.9852-Week Range$1.23Now: $2.45▼$4.23Volume199,801 shsAverage Volume942,273 shsMarket Capitalization$166.04 millionP/E RatioN/ADividend YieldN/ABeta-1.81 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops orally administered small molecule drug candidates to fill unmet medical needs. The company is developing Azeliragon, an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase II/III clinical trials for the treatment of mild Alzheimer's disease. It is also developing TTP399, an orally administered, liver-selective glucokinase activator that has completed Phase IIb clinical trials to treat type 2 diabetes, as well as is in Phase II clinical trials for treating type 1 diabetes; and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor, which has completed Phase II clinical trials for the treatment of type 2 diabetes. In addition, the company is developing a portfolio of investigational drug candidates, such as HPP737 and HPP971 to treat inflammatory disorders. It has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593. vTv Therapeutics Inc. also has license and research agreements with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; Novo Nordisk A/S; and Columbia University. The company was founded in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingvTv Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $7.00, vTv Therapeutics has a potential upside of 185.7% from its current price of $2.45.Amount of Analyst CoveragevTv Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 2.6 Community Rank Outperform VotesvTv Therapeutics has received 335 “outperform” votes. (Add your “outperform” vote.)Underperform VotesvTv Therapeutics has received 312 “underperform” votes. (Add your “underperform” vote.)Community SentimentvTv Therapeutics has received 51.78% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about vTv Therapeutics and other stocks. Vote “Outperform” if you believe VTVT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe VTVT will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldvTv Therapeutics does not currently pay a dividend.Dividend GrowthvTv Therapeutics does not have a long track record of dividend growth. Previous Next 3.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, vTv Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,030,000.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 1.50% of the stock of vTv Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 3.43% of the stock of vTv Therapeutics is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for vTv Therapeutics are expected to decrease in the coming year, from ($0.43) to ($0.59) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of vTv Therapeutics is -5.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of vTv Therapeutics is -5.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.82 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:VTVT Previous Symbol CUSIPN/A CIK1641489 Webwww.vtvtherapeutics.com Phone336-841-0300Debt Debt-to-Equity RatioN/A Current Ratio0.59 Quick Ratio0.29Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$2.76 million Price / Sales60.16 Cash FlowN/A Price / Cash FlowN/A Book Value($1.03) per share Price / Book-2.38Profitability EPS (Most Recent Fiscal Year)($0.37) Net Income$-13,040,000.00 Net Margins-870.88% Return on EquityN/A Return on Assets-178.80%Miscellaneous Employees52 Outstanding Shares67,770,000Market Cap$166.04 million Next Earnings Date11/4/2020 (Estimated) OptionableNot Optionable $2.45 -0.01 (-0.41 %) (As of 08/6/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive VTVT News and Ratings via Email Sign-up to receive the latest news and ratings for VTVT and its competitors with MarketBeat's FREE daily newsletter. vTv Therapeutics (NASDAQ:VTVT) Frequently Asked Questions How has vTv Therapeutics' stock been impacted by COVID-19 (Coronavirus)? vTv Therapeutics' stock was trading at $2.43 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, VTVT shares have increased by 0.8% and is now trading at $2.45. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of vTv Therapeutics? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for vTv Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for vTv Therapeutics. When is vTv Therapeutics' next earnings date? vTv Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020. View our earnings forecast for vTv Therapeutics. How were vTv Therapeutics' earnings last quarter? vTv Therapeutics Inc (NASDAQ:VTVT) released its earnings results on Monday, August, 3rd. The biotechnology company reported ($0.08) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.10) by $0.02. View vTv Therapeutics' earnings history. What price target have analysts set for VTVT? 2 Wall Street analysts have issued 12-month price targets for vTv Therapeutics' shares. Their forecasts range from $6.00 to $8.00. On average, they anticipate vTv Therapeutics' share price to reach $7.00 in the next twelve months. This suggests a possible upside of 185.7% from the stock's current price. View analysts' price targets for vTv Therapeutics. Has vTv Therapeutics been receiving favorable news coverage? News headlines about VTVT stock have been trending positive this week, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. vTv Therapeutics earned a coverage optimism score of 2.1 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news about vTv Therapeutics. Are investors shorting vTv Therapeutics? vTv Therapeutics saw a decline in short interest in July. As of July 31st, there was short interest totaling 1,900,000 shares, a decline of 9.5% from the July 15th total of 2,100,000 shares. Based on an average daily volume of 427,500 shares, the days-to-cover ratio is currently 4.4 days. Approximately 21.8% of the company's shares are sold short. View vTv Therapeutics' Current Options Chain. Who are some of vTv Therapeutics' key competitors? Some companies that are related to vTv Therapeutics include Trillium Therapeutics (TRIL), ORIC Pharmaceuticals (ORIC), Aprea Therapeutics (APRE), Stemline Therapeutics (STML), Vanda Pharmaceuticals (VNDA), BIOFRONTERA AG/ADR (BFRA), Basilea Pharmaceutica (BPMUF), Applied Therapeutics (APLT), Collegium Pharmaceutical (COLL), Kadmon (KDMN), Homology Medicines (FIXX), G1 Therapeutics (GTHX), Cue Biopharma (CUE), Mirum Pharmaceuticals (MIRM) and Emisphere Technologies (EMIS). View all competitors. What other stocks do shareholders of vTv Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other vTv Therapeutics investors own include VBI Vaccines (VBIV), Agile Therapeutics (AGRX), Sorrento Therapeutics (SRNE), Crispr Therapeutics (CRSP), Opko Health (OPK), Amarin (AMRN), Advanced Micro Devices (AMD), Anavex Life Sciences (AVXL), Inovio Pharmaceuticals (INO) and Trevena (TRVN). Who are vTv Therapeutics' key executives? vTv Therapeutics' management team includes the following people: Mr. Jeffrey B. Kindler, Exec. Chairman (Age 63)Mr. Stephen L. Holcombe, Pres & CEO (Age 62)Mr. Rudy C. Howard CPA, B.A., CPA, Exec. VP & CFO (Age 61)Dr. Carmen Valcarce Ph.D., Chief Scientific Officer & Exec. VPMs. Robin E. Abrams, Exec. VP & Gen. Counsel (Age 55) When did vTv Therapeutics IPO? (VTVT) raised $125 million in an initial public offering on Thursday, July 30th 2015. The company issued 7,800,000 shares at $15.00-$17.00 per share. Piper Jaffray and Stifel acted as the underwriters for the IPO and Canaccord Genuity and Janney Montgomery Scott were co-managers. What is vTv Therapeutics' stock symbol? vTv Therapeutics trades on the NASDAQ under the ticker symbol "VTVT." Who are vTv Therapeutics' major shareholders? vTv Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Wedbush Securities Inc. (0.03%). Company insiders that own vTv Therapeutics stock include Hersh Kozlov, Paul G Savas and Ronald O Perelman. View institutional ownership trends for vTv Therapeutics. Which institutional investors are buying vTv Therapeutics stock? VTVT stock was purchased by a variety of institutional investors in the last quarter, including Wedbush Securities Inc.. Company insiders that have bought vTv Therapeutics stock in the last two years include Hersh Kozlov, Paul G Savas, and Ronald O Perelman. View insider buying and selling activity for vTv Therapeutics. How do I buy shares of vTv Therapeutics? Shares of VTVT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is vTv Therapeutics' stock price today? One share of VTVT stock can currently be purchased for approximately $2.45. How big of a company is vTv Therapeutics? vTv Therapeutics has a market capitalization of $166.04 million and generates $2.76 million in revenue each year. The biotechnology company earns $-13,040,000.00 in net income (profit) each year or ($0.37) on an earnings per share basis. vTv Therapeutics employs 52 workers across the globe. What is vTv Therapeutics' official website? The official website for vTv Therapeutics is www.vtvtherapeutics.com. How can I contact vTv Therapeutics? vTv Therapeutics' mailing address is 3980 PREMIER DR SUITE 310, HIGH POINT NC, 27265. The biotechnology company can be reached via phone at 336-841-0300 or via email at [email protected] This page was last updated on 8/7/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
